The University of Chicago Header Logo

James Dignam

Concepts (417)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Prostatic Neoplasms
30
2026
1846
2.660
Why?
Breast Neoplasms
53
2026
3303
2.210
Why?
Randomized Controlled Trials as Topic
28
2026
995
2.160
Why?
Antineoplastic Agents, Hormonal
20
2026
161
2.090
Why?
Androgen Antagonists
14
2026
157
2.070
Why?
Research Design
12
2025
652
2.040
Why?
Neoplasm Recurrence, Local
25
2026
1538
1.720
Why?
Tamoxifen
21
2026
177
1.470
Why?
Brain Neoplasms
9
2025
845
1.240
Why?
Glioblastoma
6
2025
301
1.220
Why?
Proportional Hazards Models
21
2024
925
1.150
Why?
Data Interpretation, Statistical
9
2024
312
1.110
Why?
Neoplasms
17
2025
3382
1.090
Why?
Clinical Trials as Topic
14
2025
1128
0.990
Why?
Prostate-Specific Antigen
12
2026
356
0.970
Why?
Clinical Trials, Phase III as Topic
6
2016
172
0.890
Why?
Statistics as Topic
2
2021
229
0.880
Why?
Models, Statistical
7
2025
602
0.850
Why?
Survival Analysis
21
2024
1530
0.770
Why?
Disease-Free Survival
30
2025
1196
0.760
Why?
Humans
133
2026
98799
0.710
Why?
Obesity
6
2021
1079
0.680
Why?
Receptors, Estrogen
17
2012
431
0.670
Why?
Antineoplastic Agents
13
2021
2386
0.640
Why?
Biomarkers, Tumor
11
2019
1786
0.630
Why?
Aged
63
2026
21986
0.600
Why?
Middle Aged
77
2026
29642
0.580
Why?
Biomarkers
4
2025
2026
0.580
Why?
Biometry
4
2025
70
0.520
Why?
Male
56
2026
47475
0.490
Why?
Antineoplastic Combined Chemotherapy Protocols
12
2025
2666
0.490
Why?
Medical Futility
1
2016
34
0.480
Why?
Prognosis
25
2024
4139
0.460
Why?
Carcinoma, Intraductal, Noninfiltrating
7
2026
137
0.460
Why?
Chemotherapy, Adjuvant
14
2011
527
0.450
Why?
Female
76
2026
51997
0.450
Why?
Risk Assessment
14
2024
2604
0.450
Why?
Salvage Therapy
3
2024
241
0.450
Why?
Mastectomy, Segmental
9
2026
119
0.450
Why?
Colonic Neoplasms
6
2016
592
0.440
Why?
Clinical Trials, Phase I as Topic
2
2015
154
0.430
Why?
Prostatectomy
6
2026
491
0.420
Why?
Maximum Tolerated Dose
1
2015
265
0.410
Why?
Radiation Oncology
2
2016
130
0.400
Why?
Odds Ratio
11
2020
728
0.390
Why?
Neoplasm Staging
19
2018
2087
0.390
Why?
Disease Progression
10
2020
1621
0.380
Why?
Treatment Outcome
24
2024
9806
0.380
Why?
Likelihood Functions
3
2014
258
0.360
Why?
Body Mass Index
5
2013
869
0.350
Why?
Clinical Trials Data Monitoring Committees
2
2016
3
0.350
Why?
Kaplan-Meier Estimate
11
2018
909
0.350
Why?
Medical Oncology
3
2024
426
0.340
Why?
Time Factors
16
2025
5586
0.340
Why?
Lymph Nodes
4
2012
563
0.330
Why?
Dose-Response Relationship, Drug
1
2015
1949
0.330
Why?
Survival Rate
17
2017
2057
0.330
Why?
Aged, 80 and over
21
2025
7461
0.320
Why?
Follow-Up Studies
17
2024
4049
0.310
Why?
Neoplasms, Second Primary
5
2006
244
0.300
Why?
Patient Compliance
1
2011
247
0.300
Why?
Psychiatric Status Rating Scales
1
2011
508
0.290
Why?
Cognition Disorders
1
2011
239
0.290
Why?
Estrogen Antagonists
5
2004
47
0.290
Why?
Lymphatic Metastasis
11
2012
519
0.280
Why?
Adult
35
2025
29698
0.280
Why?
Combined Modality Therapy
14
2026
1754
0.280
Why?
Risk Factors
16
2024
6295
0.270
Why?
Multicenter Studies as Topic
6
2012
195
0.270
Why?
Health Status Disparities
2
2011
246
0.260
Why?
Patient Reported Outcome Measures
2
2020
337
0.250
Why?
DNA Modification Methylases
2
2025
36
0.250
Why?
DNA Repair Enzymes
2
2025
65
0.250
Why?
Oropharyngeal Neoplasms
2
2018
152
0.240
Why?
Pleural Neoplasms
3
2013
204
0.240
Why?
Neoplasm Grading
8
2024
425
0.240
Why?
United States
19
2025
8387
0.240
Why?
Margins of Excision
1
2026
50
0.240
Why?
Quality of Life
6
2025
1904
0.240
Why?
Mesothelioma
4
2013
342
0.230
Why?
Cause of Death
3
2019
279
0.230
Why?
Genes, BRCA1
4
2008
191
0.220
Why?
Health Services Accessibility
4
2021
548
0.220
Why?
Drug Administration Schedule
5
2018
837
0.220
Why?
Tumor Suppressor Proteins
2
2025
318
0.220
Why?
Radiotherapy Dosage
4
2025
478
0.210
Why?
Estrogen Receptor Modulators
2
2003
10
0.210
Why?
Endpoint Determination
3
2020
65
0.210
Why?
Tosyl Compounds
3
2021
14
0.200
Why?
Incidence
6
2022
1798
0.190
Why?
Double-Blind Method
10
2026
1793
0.190
Why?
Radiotherapy
6
2017
325
0.190
Why?
Anilides
3
2021
50
0.190
Why?
Nitriles
3
2021
172
0.180
Why?
Radiation Pneumonitis
1
2022
23
0.180
Why?
Dacarbazine
4
2017
104
0.180
Why?
Carcinoma, Ductal, Breast
3
2002
167
0.180
Why?
Mass Screening
4
2019
753
0.180
Why?
Neoplasm Metastasis
8
2021
1102
0.180
Why?
Rectal Neoplasms
1
2003
139
0.170
Why?
Immunotherapy
2
2024
831
0.160
Why?
Social Class
2
2016
156
0.160
Why?
Antineoplastic Agents, Alkylating
4
2017
136
0.160
Why?
Electronic Mail
1
2020
17
0.160
Why?
Lung Neoplasms
4
2022
2474
0.160
Why?
Pneumonia
1
2022
195
0.160
Why?
Coronavirus
1
2020
21
0.160
Why?
Clinical Trials, Phase II as Topic
3
2012
168
0.160
Why?
Kallikreins
1
2020
47
0.160
Why?
Hypersensitivity
1
2022
167
0.150
Why?
Treatment Failure
4
2017
300
0.150
Why?
Patient Readmission
1
2024
441
0.150
Why?
Lung Diseases, Interstitial
1
2024
331
0.150
Why?
Confidence Intervals
2
2014
221
0.150
Why?
Head and Neck Neoplasms
4
2011
1091
0.150
Why?
Longitudinal Studies
3
2025
1305
0.150
Why?
Carcinoma, Squamous Cell
3
2018
1107
0.150
Why?
Risk
5
2019
662
0.140
Why?
Educational Status
3
2020
206
0.140
Why?
MutL Protein Homolog 1
1
2019
36
0.140
Why?
Breast
3
2013
317
0.140
Why?
Cisplatin
2
2018
578
0.140
Why?
DNA Mismatch Repair
1
2019
60
0.140
Why?
Biomedical Research
1
2004
477
0.140
Why?
Tobacco Smoking
1
2018
33
0.140
Why?
Radiotherapy, Intensity-Modulated
4
2025
200
0.140
Why?
Radiosurgery
1
2022
352
0.140
Why?
Papillomavirus Infections
2
2018
311
0.140
Why?
Cetuximab
1
2018
119
0.140
Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
2019
54
0.140
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2018
110
0.130
Why?
Computer Simulation
4
2014
1152
0.130
Why?
Patient Participation
1
2020
251
0.130
Why?
Tumor Suppressor Protein p53
2
2012
470
0.130
Why?
Proto-Oncogene Proteins B-raf
1
2019
170
0.130
Why?
Life Expectancy
2
2009
93
0.130
Why?
Prospective Studies
7
2022
4837
0.130
Why?
Receptors, Progesterone
5
2012
208
0.130
Why?
DNA Methylation
5
2025
735
0.120
Why?
Radiotherapy, Adjuvant
3
2026
325
0.120
Why?
Genes, BRCA2
2
2008
162
0.120
Why?
SEER Program
3
2019
252
0.120
Why?
Socioeconomic Factors
4
2010
675
0.120
Why?
Cardiovascular Diseases
1
2024
824
0.120
Why?
Healthcare Disparities
2
2021
558
0.120
Why?
Internal-External Control
1
2016
47
0.120
Why?
Coronary Disease
1
1997
227
0.120
Why?
Electronic Health Records
1
2020
456
0.110
Why?
Religion
1
2016
101
0.110
Why?
Nomograms
2
2012
34
0.110
Why?
Pneumonia, Viral
1
2020
343
0.110
Why?
Coronavirus Infections
1
2020
339
0.110
Why?
Mammography
4
2013
505
0.110
Why?
Probability
1
2016
356
0.110
Why?
Epidemiologic Research Design
1
2014
23
0.110
Why?
Health Literacy
1
2016
92
0.100
Why?
Regression Analysis
2
2014
578
0.100
Why?
Pandemics
1
2020
923
0.100
Why?
Registries
3
2024
1133
0.100
Why?
Angiogenesis Inhibitors
2
2014
281
0.100
Why?
ErbB Receptors
3
2012
517
0.100
Why?
Estrogen Replacement Therapy
1
2013
52
0.100
Why?
Quality Assurance, Health Care
2
2012
229
0.100
Why?
alpha-Tocopherol
1
2013
9
0.100
Why?
Cohort Studies
5
2022
3242
0.100
Why?
Selenomethionine
1
2013
11
0.100
Why?
Cyclophosphamide
4
2012
285
0.100
Why?
Carcinoma, Non-Small-Cell Lung
1
2022
1177
0.100
Why?
Retrospective Studies
7
2024
11104
0.090
Why?
Anticarcinogenic Agents
1
2013
71
0.090
Why?
Age Factors
5
2020
1976
0.090
Why?
Radiation-Sensitizing Agents
1
2012
99
0.090
Why?
Drug Dosage Calculations
1
2012
15
0.090
Why?
Arsenic Poisoning
1
2013
104
0.090
Why?
Early Detection of Cancer
2
2014
563
0.090
Why?
Pulmonary Diffusing Capacity
1
2012
24
0.090
Why?
Drug Design
1
2012
136
0.090
Why?
Body Weight
3
2013
457
0.090
Why?
Genetic Predisposition to Disease
3
2019
2588
0.090
Why?
Antioxidants
1
2013
236
0.090
Why?
Bias
3
2025
140
0.090
Why?
Predictive Value of Tests
4
2020
1792
0.080
Why?
Health Knowledge, Attitudes, Practice
1
2016
608
0.080
Why?
Doxorubicin
2
2012
285
0.080
Why?
Antibodies, Monoclonal, Humanized
2
2014
1105
0.080
Why?
Comorbidity
2
2024
1037
0.080
Why?
Neoplasm Invasiveness
3
2008
583
0.080
Why?
Stroke
1
2000
1163
0.080
Why?
Decision Making
3
2016
691
0.080
Why?
Chemoradiotherapy
3
2018
337
0.080
Why?
Death Certificates
1
2009
11
0.080
Why?
Genes, erbB-2
1
2009
25
0.070
Why?
Adenocarcinoma
1
2017
1215
0.070
Why?
Pneumonectomy
1
2012
222
0.070
Why?
Quinazolines
1
2010
222
0.070
Why?
Neuropsychological Tests
1
2011
571
0.070
Why?
Neoadjuvant Therapy
1
2012
477
0.070
Why?
Population Surveillance
1
2009
218
0.070
Why?
Time
1
2008
80
0.070
Why?
Germ-Line Mutation
2
2019
404
0.070
Why?
Fanconi Anemia Complementation Group F Protein
1
2007
6
0.070
Why?
Ovariectomy
1
2008
98
0.070
Why?
Fallopian Tubes
1
2008
49
0.070
Why?
Skin Neoplasms
1
2013
638
0.070
Why?
Analysis of Variance
2
2012
890
0.060
Why?
Prevalence
2
2024
1396
0.060
Why?
Quality Improvement
1
2012
538
0.060
Why?
Mutation
3
2008
4443
0.060
Why?
Colorectal Neoplasms
2
2006
1120
0.060
Why?
Disclosure
1
2007
98
0.060
Why?
Parent-Child Relations
1
2007
89
0.060
Why?
Ubiquitin-Protein Ligases
1
2007
188
0.060
Why?
Estrogen Receptor alpha
1
2007
159
0.060
Why?
Survival
1
2006
22
0.060
Why?
Flutamide
2
2017
3
0.060
Why?
Goserelin
2
2017
5
0.060
Why?
Disability Evaluation
1
2007
185
0.060
Why?
Vulnerable Populations
1
2007
101
0.060
Why?
Aneuploidy
1
2005
60
0.060
Why?
Steroid 17-alpha-Hydroxylase
1
2025
16
0.060
Why?
Chromosomes, Human, Pair 17
1
2005
110
0.060
Why?
Geriatric Assessment
1
2007
193
0.060
Why?
Proton Therapy
2
2016
44
0.060
Why?
North America
1
2005
211
0.060
Why?
Control Groups
1
2025
16
0.060
Why?
Ipilimumab
1
2025
69
0.060
Why?
Bayes Theorem
2
2014
423
0.050
Why?
Growth Inhibitors
1
2004
41
0.050
Why?
Brachytherapy
1
2025
139
0.050
Why?
Selective Estrogen Receptor Modulators
1
2004
34
0.050
Why?
Technology, Radiologic
2
2016
105
0.050
Why?
Logistic Models
2
2020
1276
0.050
Why?
Statistics, Nonparametric
1
2004
304
0.050
Why?
Cancer Care Facilities
1
2003
43
0.050
Why?
Body Composition
1
2003
88
0.050
Why?
Interprofessional Relations
1
2004
122
0.050
Why?
Travel
1
2003
80
0.050
Why?
Proto-Oncogene Proteins c-myc
1
2004
160
0.050
Why?
National Institutes of Health (U.S.)
1
2004
140
0.050
Why?
Transcription Factors
1
2011
1724
0.050
Why?
Phosphoproteins
1
2004
264
0.050
Why?
Lomustine
2
2012
24
0.050
Why?
Neoplasms, Experimental
1
2004
263
0.050
Why?
Chicago
2
2024
1520
0.050
Why?
Cooperative Behavior
1
2004
199
0.050
Why?
Consensus
1
2004
308
0.050
Why?
National Cancer Institute (U.S.)
2
2012
77
0.040
Why?
Bevacizumab
2
2014
255
0.040
Why?
Interferon-gamma
1
2004
478
0.040
Why?
Pancreatic Neoplasms
1
2008
782
0.040
Why?
Young Adult
2
2012
7598
0.040
Why?
Hematuria
1
2022
53
0.040
Why?
Models, Theoretical
1
2004
510
0.040
Why?
Trans-Activators
1
2004
447
0.040
Why?
Carcinoma in Situ
2
1999
55
0.040
Why?
Sex Factors
1
2024
1144
0.040
Why?
Computational Biology
1
2024
620
0.040
Why?
Tumor Necrosis Factor-alpha
1
2004
712
0.040
Why?
Selection Bias
1
2020
40
0.040
Why?
Multivariate Analysis
3
2011
1007
0.040
Why?
Monte Carlo Method
2
2014
194
0.040
Why?
Precision Medicine
1
2025
512
0.040
Why?
Platelet Aggregation Inhibitors
1
2022
194
0.040
Why?
Symptom Assessment
1
2020
77
0.040
Why?
Databases, Factual
1
2024
1102
0.040
Why?
Chi-Square Distribution
1
2020
361
0.040
Why?
Prostate
1
2023
434
0.040
Why?
Patient Selection
1
2003
725
0.040
Why?
Contrast Media
1
2004
1014
0.040
Why?
United States Department of Veterans Affairs
1
2019
50
0.040
Why?
Surveys and Questionnaires
2
2019
3058
0.040
Why?
Radiotherapy, Conformal
1
2019
88
0.030
Why?
Mastectomy
3
2012
277
0.030
Why?
Tomography, X-Ray Computed
3
2013
2680
0.030
Why?
Promoter Regions, Genetic
3
2007
979
0.030
Why?
Signal Transduction
2
2012
3642
0.030
Why?
Anticoagulants
1
2022
486
0.030
Why?
China
1
2019
283
0.030
Why?
DNA-Binding Proteins
1
2004
1275
0.030
Why?
Fluorouracil
3
2011
543
0.030
Why?
DNA Copy Number Variations
1
2019
207
0.030
Why?
Cranial Irradiation
1
2017
42
0.030
Why?
Informed Consent
1
2020
281
0.030
Why?
Re-Irradiation
1
2017
18
0.030
Why?
Betacoronavirus
1
2020
288
0.030
Why?
Gynecomastia
1
2017
8
0.030
Why?
Canada
2
2011
210
0.030
Why?
Diffusion of Innovation
1
2016
81
0.030
Why?
Costs and Cost Analysis
1
2016
155
0.030
Why?
Research Personnel
1
2016
90
0.030
Why?
Leucovorin
2
2011
205
0.030
Why?
Income
1
2016
103
0.030
Why?
Program Evaluation
1
2016
349
0.030
Why?
Leuprolide
1
2014
34
0.030
Why?
Radiation Injuries
1
2016
160
0.030
Why?
Genomics
1
2021
914
0.030
Why?
Urban Population
1
2016
254
0.030
Why?
Information Dissemination
1
1995
135
0.030
Why?
Markov Chains
1
2014
155
0.030
Why?
Quality-Adjusted Life Years
1
2014
170
0.030
Why?
Social Support
1
2016
246
0.020
Why?
Myocardial Infarction
1
1997
397
0.020
Why?
Attitude of Health Personnel
1
1998
688
0.020
Why?
Lung Volume Measurements
1
2013
24
0.020
Why?
Ethics, Medical
1
1995
292
0.020
Why?
Cytostatic Agents
1
2012
4
0.020
Why?
Postmenopause
1
2013
109
0.020
Why?
Cytotoxins
1
2012
18
0.020
Why?
Pemetrexed
1
2012
76
0.020
Why?
Glutamates
1
2012
85
0.020
Why?
Karnofsky Performance Status
1
2012
43
0.020
Why?
Sample Size
1
2012
130
0.020
Why?
Sentinel Lymph Node Biopsy
1
2012
88
0.020
Why?
Credentialing
1
2012
15
0.020
Why?
Body Surface Area
1
2012
38
0.020
Why?
Taxoids
1
2012
127
0.020
Why?
Magnetic Resonance Imaging
1
2004
3622
0.020
Why?
Bangladesh
1
2013
366
0.020
Why?
Cell Hypoxia
1
2012
191
0.020
Why?
Guanine
1
2012
194
0.020
Why?
Levamisole
1
2011
6
0.020
Why?
Cost-Benefit Analysis
2
2005
521
0.020
Why?
Sensitivity and Specificity
2
2007
1946
0.020
Why?
Immunoenzyme Techniques
1
2012
291
0.020
Why?
Preoperative Period
1
2012
103
0.020
Why?
Deoxycytidine
1
2012
218
0.020
Why?
Vincristine
1
2011
102
0.020
Why?
Immunologic Factors
1
2012
180
0.020
Why?
Zinc Finger Protein GLI1
1
2011
21
0.020
Why?
Antimetabolites, Antineoplastic
2
2005
246
0.020
Why?
Tissue Array Analysis
1
2011
135
0.020
Why?
DNA Repair
1
2012
363
0.020
Why?
DNA Damage
1
2012
400
0.020
Why?
Molecular Targeted Therapy
1
2012
331
0.020
Why?
Glioma
1
2012
310
0.020
Why?
Senegal
1
2009
4
0.020
Why?
beta Catenin
1
2011
269
0.020
Why?
Evidence-Based Medicine
1
2012
483
0.020
Why?
Nigeria
1
2009
174
0.020
Why?
Health Surveys
1
2009
254
0.020
Why?
RNA, Messenger
2
2005
2076
0.020
Why?
Cell Line, Tumor
2
2005
2913
0.020
Why?
Pharmacogenetics
1
2012
474
0.020
Why?
Genetic Carrier Screening
1
2008
58
0.020
Why?
Reproducibility of Results
1
2014
2799
0.020
Why?
Risk Reduction Behavior
1
2008
102
0.020
Why?
Gene Expression Regulation, Neoplastic
1
2012
1400
0.020
Why?
CpG Islands
1
2007
177
0.020
Why?
Immunohistochemistry
1
2011
1818
0.020
Why?
Methotrexate
2
1997
229
0.010
Why?
Practice Patterns, Physicians'
1
2012
669
0.010
Why?
Pedigree
1
2008
988
0.010
Why?
Data Collection
1
2007
376
0.010
Why?
Activities of Daily Living
1
2007
214
0.010
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2007
889
0.010
Why?
Hydroxamic Acids
1
2005
53
0.010
Why?
Models, Econometric
1
2005
15
0.010
Why?
Disease Models, Animal
1
2012
2581
0.010
Why?
Value of Life
1
2005
23
0.010
Why?
Adolescent
2
2009
10168
0.010
Why?
Stochastic Processes
1
2005
77
0.010
Why?
Gene Dosage
1
2005
216
0.010
Why?
Azacitidine
1
2005
152
0.010
Why?
Minority Groups
1
2006
166
0.010
Why?
ROC Curve
1
2007
797
0.010
Why?
Single-Blind Method
1
2004
160
0.010
Why?
Interferon Regulatory Factor-1
1
2004
18
0.010
Why?
BRCA1 Protein
1
2005
222
0.010
Why?
Interleukin-18
1
2004
27
0.010
Why?
Lymphopenia
1
2004
31
0.010
Why?
Receptors, Interferon
1
2004
32
0.010
Why?
Genetic Testing
1
2008
610
0.010
Why?
Pilot Projects
1
2007
978
0.010
Why?
STAT1 Transcription Factor
1
2004
60
0.010
Why?
Lymphocytes
1
2005
461
0.010
Why?
Case-Control Studies
1
2008
2017
0.010
Why?
Interleukin-12
1
2004
110
0.010
Why?
Gene Silencing
1
2004
178
0.010
Why?
Pyrroles
1
2004
166
0.010
Why?
Gadolinium DTPA
1
2004
239
0.010
Why?
Hospitals, University
1
2003
192
0.010
Why?
Bone Marrow Transplantation
1
2004
287
0.010
Why?
In Situ Hybridization, Fluorescence
1
2004
369
0.010
Why?
Quality of Health Care
1
2006
400
0.010
Why?
Protein-Tyrosine Kinases
1
2004
305
0.010
Why?
Cell Division
1
2004
690
0.010
Why?
Indoles
1
2004
340
0.010
Why?
Transfection
1
2004
884
0.010
Why?
Mice, Nude
1
2004
829
0.010
Why?
Killer Cells, Natural
1
2004
298
0.010
Why?
Cognition
1
2007
672
0.010
Why?
Gene Expression
1
2005
1322
0.010
Why?
Ovarian Neoplasms
1
2008
829
0.010
Why?
Recurrence
1
2004
1274
0.010
Why?
Meta-Analysis as Topic
1
2001
87
0.010
Why?
Cross-Sectional Studies
1
2007
2077
0.010
Why?
Muscle, Skeletal
1
2004
523
0.010
Why?
Alleles
1
2004
1163
0.010
Why?
Referral and Consultation
1
2003
419
0.010
Why?
Melanoma
1
2004
523
0.010
Why?
Liver
1
2004
1231
0.010
Why?
Genotype
1
2004
1895
0.010
Why?
B-Lymphocytes
1
2004
737
0.010
Why?
Animals
2
2012
29045
0.010
Why?
Necrosis
1
1999
225
0.010
Why?
Mice, Knockout
1
2004
2217
0.010
Why?
Carcinoma, Lobular
1
1999
84
0.010
Why?
Neoplasm, Residual
1
1999
205
0.010
Why?
Liver Neoplasms
1
2004
840
0.010
Why?
T-Lymphocytes
1
2004
1335
0.010
Why?
Phenotype
1
2004
2673
0.010
Why?
Mice, Inbred C57BL
1
2004
3628
0.010
Why?
Federal Government
1
1995
28
0.010
Why?
Child
1
2007
7771
0.010
Why?
Government Regulation
1
1995
49
0.010
Why?
Endometrial Neoplasms
1
1996
243
0.010
Why?
Mice
1
2004
12762
0.000
Why?
Dignam's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (417)
Explore
_
Co-Authors (47)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_